| Trial ID: | L5623 |
| Source ID: | NCT01511185
|
| Associated Drug: |
Liraglutide
|
| Title: |
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide|DRUG: placebo
|
| Outcome Measures: |
Primary: AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval | Secondary: Slope of the mean ISR vs mean glucose|AUC (area under the curve) of glucagon concentration over the 90-216 mg/dL glucose interval|Insulin Clearance|NNC 90-1 170 plasma concentration|Adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2001-02
|
| Completion Date: |
2001-10
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-26
|
| Locations: |
Novo Nordisk Investigational Site, Ann Arbor, Michigan, 48109-0926, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01511185
|
